{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Digestive+System+Neuroendocrine+Tumor+G1&page=2", "query": { "condition": "Metastatic Digestive System Neuroendocrine Tumor G1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Digestive+System+Neuroendocrine+Tumor+G1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T10:23:19.688Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00087191", "title": "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Fallopian Tube Cancer", "Gastrointestinal Stromal Tumor", "Localized Extrahepatic Bile Duct Cancer", "Localized Gallbladder Cancer", "Localized Gastrointestinal Carcinoid Tumor", "Localized Resectable Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Primary Peritoneal Cavity Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Colon Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Small Intestine Cancer", "Recurrent Uterine Sarcoma", "Regional Gastrointestinal Carcinoid Tumor", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage 0 Non-small Cell Lung Cancer", "Stage I Adult Soft Tissue Sarcoma", "Stage I Colon Cancer", "Stage I Gastric Cancer", "Stage I Non-small Cell Lung Cancer", "Stage I Ovarian Epithelial Cancer", "Stage I Ovarian Germ Cell Tumor", "Stage I Pancreatic Cancer", "Stage I Rectal Cancer", "Stage I Uterine Sarcoma", "Stage II Adult Soft Tissue Sarcoma", "Stage II Colon Cancer", "Stage II Gastric Cancer", "Stage II Non-small Cell Lung Cancer", "Stage II Ovarian Epithelial Cancer", "Stage II Ovarian Germ Cell Tumor", "Stage II Pancreatic Cancer", "Stage II Rectal Cancer", "Stage II Uterine Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Colon Cancer", "Stage III Gastric Cancer", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Uterine Sarcoma", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Uterine Sarcoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "EF5", "type": "DRUG" }, { "name": "motexafin lutetium", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087191" }, { "nct_id": "NCT03375320", "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Functioning Pancreatic Neuroendocrine Tumor", "Intermediate Grade Lung Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Tumor G1", "Locally Advanced Lung Neuroendocrine Neoplasm", "Locally Advanced Pancreatic Neuroendocrine Tumor", "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm", "Low Grade Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor", "Lung Neuroendocrine Tumor G2", "Metastatic Digestive System Neuroendocrine Neoplasm", "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Metastatic Pancreatic Neuroendocrine Neoplasm", "Metastatic Pancreatic Neuroendocrine Tumor", "Metastatic Thymus Neuroendocrine Neoplasm", "Neuroendocrine Neoplasm", "Neuroendocrine Tumor", "Neuroendocrine Tumor G2", "Non-Functioning Pancreatic Neuroendocrine Tumor", "Pancreatic Serotonin-Producing Neuroendocrine Tumor", "Thymus Neuroendocrine Tumor", "Unresectable Digestive System Neuroendocrine Neoplasm", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Pancreatic Neuroendocrine Neoplasm", "Unresectable Thymus Neuroendocrine Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2018-10-26", "completion_date": "2026-08-19", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 433, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 290 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03375320" }, { "nct_id": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Anaplastic Thyroid Cancer", "Bone Metastases", "Carcinoma of the Appendix", "Distal Urethral Cancer", "Fallopian Tube Cancer", "Gastrinoma", "Glucagonoma", "Inflammatory Breast Cancer", "Insulinoma", "Liver Metastases", "Localized Unresectable Adult Primary Liver Cancer", "Lung Metastases", "Male Breast Cancer", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Parathyroid Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Newly Diagnosed Carcinoma of Unknown Primary", "Occult Non-small Cell Lung Cancer", "Pancreatic Polypeptide Tumor", "Primary Peritoneal Cavity Cancer", "Proximal Urethral Cancer", "Pulmonary Carcinoid Tumor", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Carcinoma of Unknown Primary", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Parathyroid Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Thyroid Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Skin Metastases", "Small Intestine Adenocarcinoma", "Somatostatinoma", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Adrenocortical Carcinoma", "Stage III Bladder Cancer", "Stage III Cervical Cancer", "Stage III Colon Cancer", "Stage III Endometrial Carcinoma", "Stage III Esophageal Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Pancreatic Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Prostate Cancer", "Stage III Rectal Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Anal Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Anal Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Adrenocortical Carcinoma", "Stage IV Anal Cancer", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Gastric Cancer", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Papillary Thyroid Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer", "WDHA Syndrome" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "ABI-007/carboplatin/trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004074" }, { "nct_id": "NCT00003548", "title": "Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aminocamptothecin colloidal dispersion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003548" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07-28", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04602117" }, { "nct_id": "NCT00003046", "title": "Interleukin-12 in Treating Patients With Cancer in the Abdomen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Cancer", "Colorectal Cancer", "Gallbladder Cancer", "Gastric Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Recombinant Interleukin-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "1997-08", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003046" }, { "nct_id": "NCT00006368", "title": "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Breast Cancer", "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Lung Cancer", "Lymphoma", "Melanoma (Skin)", "Neoplastic Syndrome" ], "interventions": [ { "name": "yttrium Y 90-edotreotide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1998-01", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-05-01", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006368" }, { "nct_id": "NCT00005860", "title": "Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "floxuridine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005860" }, { "nct_id": "NCT00227617", "title": "Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Lung Cancer", "Neoplastic Syndrome", "Neuroendocrine Tumor" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-06-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-06-10T10:23:19.688Z", "location_count": 2, "location_summary": "San Francisco, California • Vallejo, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227617" } ] }